牛牛AI助手已提取核心信息
EyePoint Pharmaceuticals, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, dated December 31, 2023. The filing indicates that RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively referred to as the Reporting Persons, have reported shared voting and dispositive power over 3,095,136 shares of EyePoint Pharmaceuticals' common stock. This represents approximately 6.1% of the company's class of securities. The Reporting Persons have entered into a Joint Filing Agreement to file a single statement on Schedule 13G/A. The filing also notes that the shares include 913,318 shares of common stock and 2,181,818 Pre-funded warrants, which are subject to a Beneficial Ownership Blocker limiting ownership to below 9.99% of the outstanding common stock. The Reporting Persons have disclaimed beneficial ownership of the securities for purposes other than determining their obligations under Section 13(d) of the Act. The filing was certified as true, complete, and correct as of February 14, 2024.
EyePoint Pharmaceuticals, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, dated December 31, 2023. The filing indicates that RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively referred to as the Reporting Persons, have reported shared voting and dispositive power over 3,095,136 shares of EyePoint Pharmaceuticals' common stock. This represents approximately 6.1% of the company's class of securities. The Reporting Persons have entered into a Joint Filing Agreement to file a single statement on Schedule 13G/A. The filing also notes that the shares include 913,318 shares of common stock and 2,181,818 Pre-funded warrants, which are subject to a Beneficial Ownership Blocker limiting ownership to below 9.99% of the outstanding common stock. The Reporting Persons have disclaimed beneficial ownership of the securities for purposes other than determining their obligations under Section 13(d) of the Act. The filing was certified as true, complete, and correct as of February 14, 2024.
EyePoint Pharmicals, Inc.是最近于2023年12月31日向美国证券交易委员会提交的附表13G/A文件的主题。文件显示，RA资本管理有限责任公司以及个人彼得·科尔钦斯基和拉杰夫·沙阿以及RA Capital Healthcare Fund, L.P.（统称为 “申报人”）报告了对EyePoint Pharmaceuticals普通股的3,095,136股的共享投票权和处置权。这约占公司证券类别的6.1％。申报人已签订联合申报协议，根据附表13G/A提交一份单一声明。该文件还指出，这些股票包括913,318股普通股和2,181,818份预先注资认股权证，受实益所有权封锁的约束，将所有权限制在已发行普通股的9.99％以下。申报人出于确定该法第13（d）条规定的义务以外的目的放弃了证券的受益所有权。截至2024年2月14日，该文件已被认证为真实、完整和正确。
EyePoint Pharmicals, Inc.是最近于2023年12月31日向美国证券交易委员会提交的附表13G/A文件的主题。文件显示，RA资本管理有限责任公司以及个人彼得·科尔钦斯基和拉杰夫·沙阿以及RA Capital Healthcare Fund, L.P.（统称为 “申报人”）报告了对EyePoint Pharmaceuticals普通股的3,095,136股的共享投票权和处置权。这约占公司证券类别的6.1％。申报人已签订联合申报协议，根据附表13G/A提交一份单一声明。该文件还指出，这些股票包括913,318股普通股和2,181,818份预先注资认股权证，受实益所有权封锁的约束，将所有权限制在已发行普通股的9.99％以下。申报人出于确定该法第13（d）条规定的义务以外的目的放弃了证券的受益所有权。截至2024年2月14日，该文件已被认证为真实、完整和正确。
有用
没用